DermTech, Inc.

Symbol: DMTK

NASDAQ

0.6906

USD

Market price today

  • -0.2126

    P/E Ratio

  • 0.0002

    PEG Ratio

  • 23.91M

    MRK Cap

  • 0.00%

    DIV Yield

DermTech, Inc. (DMTK) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.02%

Operating Profit Margin

-6.78%

Net Profit Margin

-6.55%

Return on Assets

-0.82%

Return on Equity

-1.23%

Return on Capital Employed

-0.96%

Company general description and statistics

Sector: Healthcare
Industry: Diagnostics & Research
CEO:Mr. Bret Christensen
Full-time employees:206
City:La Jolla
Address:11099 North Torrey Pines Road
IPO:2017-08-10
CIK:0001651944

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

General Outlook

When we look at how much money they make before expenses, they keep 0.018% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -6.782%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -6.545%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.821% return, is a testament to DermTech, Inc.'s adeptness in optimizing resource deployment. DermTech, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -1.230%. Furthermore, the proficiency of DermTech, Inc. in capital utilization is underscored by a remarkable -0.956% return on capital employed.

Stock Prices

DermTech, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.65, while its low point bottomed out at $0.601. This variance in figures offers investors a lucid insight into the roller-coaster ride that is DermTech, Inc.'s stock market.

Liquidity Ratios

Analyzing DMTK liquidity ratios reveals its financial health of the firm. The current ratio of 459.23% gauges short-term asset coverage for liabilities. The quick ratio (434.65%) assesses immediate liquidity, while the cash ratio (273.23%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio459.23%
Quick Ratio434.65%
Cash Ratio273.23%

Profitability Ratios

DMTK profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -659.57% underscores its earnings before tax deductions. The net income per EBT, 99.23%, and the EBT per EBIT, 97.25%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -678.21%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-659.57%
Net Income per EBT99.23%
EBT per EBIT97.25%
EBIT per Revenue-678.21%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 4.59, it details the span from stock purchase to revenue. The 4 days it takes to settle debts showcases its creditor relations. Meanwhile, a 3 cash conversion cycle and 591.95% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding435
Days of Inventory Outstanding24
Operating Cycle86.06
Days of Payables Outstanding36
Cash Conversion Cycle50
Receivables Turnover5.92
Payables Turnover10.12
Inventory Turnover14.96
Fixed Asset Turnover0.27
Asset Turnover0.13

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -2.24, and free cash flow per share, -2.27, depict cash generation on a per-share basis. The cash per share value, 1.63, showcases liquidity position. Lastly, the operating cash flow sales ratio, -5.03, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-2.24
Free Cash Flow per Share-2.27
Cash per Share1.63
Operating Cash Flow Sales Ratio-5.03
Free Cash Flow to Operating Cash Flow Ratio1.01
Cash Flow Coverage Ratio-1.42
Short Term Coverage Ratio-24.94
Capital Expenditure Coverage Ratio-85.34
Dividend Paid and Capex Coverage Ratio-85.34

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 44.61%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.95, we discern the balance between debt and equity financing. The long-term debt to capitalization, 47.30%, and total debt to capitalization, 48.75%, ratios shed light on its capital structure.

cards.indicatorcards.value
Debt Ratio44.61%
Debt Equity Ratio0.95
Long Term Debt to Capitalization47.30%
Total Debt to Capitalization48.75%
Cash Flow to Debt Ratio-1.42
Company Equity Multiplier2.13

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.47, provides a glimpse into top-line earnings distributed across each share. Net income per share, -3.09, reflects the portion of profit attributed to each share. The book value per share, 1.75, represents the net asset value distributed per share, while the tangible book value per share, 1.75, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.47
Net Income Per Share-3.09
Book Value Per Share1.75
Tangible Book Value Per Share1.75
Shareholders Equity Per Share1.75
Interest Debt Per Share1.67
Capex Per Share-0.03

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 5.36%, indicates top-line expansion, while the gross profit growth, -57.34%, reveals profitability trends. EBIT growth, 12.21%, and operating income growth, 12.21%, offer insights into operational profitability progression. The net income growth, 11.28%, showcases bottom-line expansion, and the EPS growth, 18.47%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth5.36%
Gross Profit Growth-57.34%
EBIT Growth12.21%
Operating Income Growth12.21%
Net Income Growth11.28%
EPS Growth18.47%
EPS Diluted Growth18.47%
Weighted Average Shares Growth8.66%
Weighted Average Shares Diluted Growth8.66%
Operating Cash Flow Growth19.19%
Free Cash Flow Growth20.99%
5-Year Revenue Growth per Share-2.42%
3-Year Revenue Growth per Share35.20%
5-Year Operating CF Growth per Share7.14%
3-Year Operating CF Growth per Share-39.60%
5-Year Net Income Growth per Share1.15%
3-Year Net Income Growth per Share-51.14%
5-Year Shareholders Equity Growth per Share-1.75%
3-Year Shareholders Equity Growth per Share-53.16%
Receivables Growth-38.06%
Inventory Growth-42.86%
Asset Growth-39.66%
Book Value per Share Growth-60.25%
Debt Growth-2.57%
R&D Expense Growth-36.64%
SGA Expenses Growth-6.31%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 74,775,408, captures the company's total value, considering both debt and equity. Income quality, 0.76, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 2.86, gauges operational efficiency, while the research and development to revenue, 99.63%, highlights investment in innovation.

cards.indicatorcards.value
Enterprise Value74,775,408
Income Quality0.76
Sales General and Administrative to Revenue2.86
Research and Development to Revenue99.63%
Capex to Operating Cash Flow1.17%
Capex to Revenue-5.90%
Capex to Depreciation-15.43%
Stock-Based Compensation to Revenue121.37%
Graham Number11.04
Return on Tangible Assets-82.74%
Graham Net Net-0.20
Working Capital48,305,000
Tangible Asset Value57,175,001
Net Current Asset Value-3,002,999
Invested Capital1
Average Receivables3,378,000
Average Payables1,951,500
Average Inventory1,380,500
Days Sales Outstanding62
Days Payables Outstanding36
Days of Inventory On Hand24
ROIC-92.98%
ROE-1.76%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.37, and the price to book ratio, 0.37, reflect the market's valuation relative to the company's book value. The price to sales ratio, 1.40, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -0.28, and price to operating cash flows, -0.28, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio0.37
Price to Book Ratio0.37
Price to Sales Ratio1.40
Price Cash Flow Ratio-0.28
Enterprise Value Multiple-0.04
Price Fair Value0.37
Price to Operating Cash Flow Ratio-0.28
Price to Free Cash Flows Ratio-0.28
Price to Tangible Book Ratio1.00
Enterprise Value to Sales4.89
Enterprise Value Over EBITDA-0.76
EV to Operating Cash Flow-0.97
Earnings Yield-176.62%
Free Cash Flow Yield-136.34%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of DermTech, Inc. (DMTK) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.213 in 2024.

What is the ticker symbol of DermTech, Inc. stock?

The ticker symbol of DermTech, Inc. stock is DMTK.

What is company IPO date?

IPO date of DermTech, Inc. is 2017-08-10.

What is company current share price?

Current share price is 0.691 USD.

What is stock market cap today?

The market cap of stock today is 23910920.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 206.